• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Collegium Pharmaceutical Inc.

    3/6/25 4:05:58 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COLL alert in real time by email
    S-8 1 tm258263d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 6, 2025

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM S-8

     

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

    Collegium Pharmaceutical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Virginia   100 Technology Center Drive
    Stoughton, MA 02072
      03-0416362
    (State or other jurisdiction of
    incorporation or organization)
      (Address, including zip code, of
    Principal Executive Offices)
      (I.R.S. Employer
    Identification No.)

     

    AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN

    2015 EMPLOYEE STOCK PURCHASE PLAN

    (Full title of the plans)

     

    Colleen Tupper

    Executive Vice President and Chief Financial Officer

    100 Technology Center Drive
    Stoughton, MA 02072

    (781) 713-3699

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Jennifer L. Porter, Esq.
    Goodwin Procter LLP
    3025 John F Kennedy Blvd
    Philadelphia, PA 19104
    (445) 207-7806
    Shirley R. Kuhlmann, Esq.
    Executive Vice President,
    Chief Administrative Officer & General Counsel
    100 Technology Center Drive, Suite 300
    Stoughton, MA 02072
    (781) 713-3699

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,572,008 shares of Common Stock of the Registrant that were added to the shares authorized for issuance under the Collegium Pharmaceutical, Inc. Amended and Restated 2014 Stock Incentive Plan (the “Stock Incentive Plan”) and the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan (the “ESPP”) for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective. Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 (File Nos. 333-207744, 333-218767, 333-225498, 333-233092, 333-245649, 333-258752, 333-266778, 333-273874 and 333-281571) filed with the Securities and Exchange Commission (the “Commission”) on November 2, 2015, June 15, 2017, June 7, 2018, August 7, 2019, August 13, 2020, August 12, 2021, August 11, 2022, August 10, 2023 and August 15, 2024 are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:

     

      (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025;

     

      (b) The Registrant’s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed on February 5, 2025 and February 27, 2025; and

     

      (c) The description of the Registrant’s Common Stock contained in the Form 8-A filed with the Commission on May 1, 2015 pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of further updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
    4.1   Third Amended and Restated Articles of Incorporation of Collegium Pharmaceutical, Inc. (1)
         
    4.2   Amended and Restated Bylaws of Collegium Pharmaceutical, Inc. (2)
         
    5.1   Opinion of Troutman Pepper Hamilton Sanders LLP
         
    23.1   Consent of Deloitte & Touche LLP
         
    23.2   Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit 5.1)
         
    24.1   Power of Attorney (included on the signature page)
         
    99.1   Amended and Restated 2014 Stock Incentive Plan (3)
         
    99.2   Form of Incentive Stock Option Agreement under the Amended and Restated 2014 Stock Incentive Plan (3)
         
    99.3   Form of Non-Qualified Stock Option Agreement under the Amended and Restated 2014 Stock Incentive Plan (3)

     

     

     

     

    99.4   Form of Restricted Stock Unit Agreement under the Amended and Restated 2014 Stock Incentive Plan (4)
         
    99.5   Form of Performance Share Unit Agreement under the Amended and Restated 2014 Stock Incentive Plan (5)
         
    99.6   2015 Employee Stock Purchase Plan (3)
         
    107   Calculation of Registration Fees

     

    (1) Previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 5, 2020.

     

    (2) Previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed with the Commission on December 4, 2017.

     

    (3) Previously filed as an exhibit to the Registrant’s Registration Statement on Form S-8 (File No. 333-207744) filed with the Commission on November 2, 2015.

     

    (4) Previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K, filed with the Commission on February 22, 2024.

     

    (5) Previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on May 8, 2019.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Stoughton, Commonwealth of Massachusetts, on this 6th day of March, 2025.

     

      COLLEGIUM PHARMACEUTICAL, INC.
       
      By: /s/ Colleen Tupper                    
        Colleen Tupper
        Executive Vice President and Chief Financial Officer

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Collegium Pharmaceutical, Inc., hereby severally constitute and appoint Vikram Karnani, Colleen Tupper and Shirley R. Kuhlmann, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said Registration Statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Collegium Pharmaceutical, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said Registration Statement and any and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities indicated on March 6, 2025.

     

    Signature   Title
         
    /s/ Vikram Karnani   President and Chief Executive Officer
    (Principal Executive Officer)
    Vikram Karnani  
         
    /s/ Colleen Tupper   Executive Vice President and Chief Financial Officer
    (Principal Financial and Accounting Officer)
    Colleen Tupper  
         
    /s/Michael Heffernan, R.Ph.   Chairman of the Board of Directors
    Michael Heffernan, R.Ph.    
         
    /s/ Rita Balice-Gordon, Ph.D.   Director
    Rita Balice-Gordon, Ph.D.    
         
    /s/ Garen G. Bohlin   Director
    Garen G. Bohlin    
         
    /s/ John A. Fallon, M.D.   Director
    John A. Fallon, M.D.    
         
    /s/ John G. Freund, M.D.   Director
    John G. Freund, M.D.    
         
    /s/ Nancy Lurker   Director
    Nancy Lurker    
         
    /s/ Gwen A. Melincoff   Director
    Gwen A. Melincoff    
         
    /s/ Gino Santini   Director
    Gino Santini    

     

     

    Get the next $COLL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COLL

    DatePrice TargetRatingAnalyst
    12/9/2025$58.00Overweight
    Barclays
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    More analyst ratings

    $COLL
    SEC Filings

    View All

    Collegium Pharmaceutical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

    1/8/26 8:06:38 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

    12/30/25 8:05:50 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.

    SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/25 2:26:29 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Commercial Officer Dreyer Scott exercised 17,600 shares at a strike of $15.90 and sold $847,855 worth of shares (17,600 units at $48.17) (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    12/10/25 4:32:40 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Balice-Gordon Rita J. sold $171,673 worth of shares (3,650 units at $47.03), decreasing direct ownership by 6% to 52,629 units (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    12/9/25 4:22:58 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Karnani Vikram covered exercise/tax liability with 8,983 shares, decreasing direct ownership by 8% to 96,989 units (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    11/14/25 4:13:00 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

    STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference being held from January 15-18, 2026, in San Diego, California. "We look forward to sharing this new data and hope that it will be v

    1/15/26 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Provides 2026 Financial Guidance and Business Update

    – Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced its 2026 full-year financial guidance and provided a business update. "2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum for continued success," said Vikram Karnani, President and Chief Executive Officer. "The outstanding performance of Jornay PM, along with sustained revenue growth acro

    1/8/26 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Announces the Closing of $980 Million Syndicated Credit Facility

    STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million credit facility will mature in 2030 and consists of a $580 million initial Term Loan, $300 million Delayed Draw Term Loan, and $100 million revolving credit facility (collectively the "Credit Facility"). The initial Term Loan was used to repay approximately $581 million of principal representing the entire remaining balance of the Company's previous $646 million term loan secured from funds managed by Pharmakon Advisors, LP. The Delayed Draw Term Loan and revolving credit facility, both of w

    12/30/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Collegium Pharmaceutical with a new price target

    Barclays initiated coverage of Collegium Pharmaceutical with a rating of Overweight and set a new price target of $58.00

    12/9/25 8:43:40 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical upgraded by Needham with a new price target

    Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

    1/10/25 8:00:15 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

    7/30/24 6:32:12 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Financials

    Live finance-specific insights

    View All

    Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

    – Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3'25 with Cash, Cash Equivalents and Marketable Securities of $285.9 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Nov. 06, 2025 (GLOBE NEW

    11/6/25 7:30:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

    STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q3 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the

    10/23/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

    – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million – – Ended Q2'25 with Cash, Cash Equivalents and Marketable Securities of $222.2 Million – – Board of Directors Authorized $150 Million Share Repurchase

    8/7/25 7:30:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Announces Updates to its Board of Directors and Executive Leadership Team

           – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

    3/17/25 7:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Appoints Nancy S. Lurker to its Board of Directors

    STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth

    2/5/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Collegium Pharmaceutical Inc.

    SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/24 5:13:28 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

    SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/24 4:30:24 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

    SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    2/14/24 12:04:28 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care